{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T07:15:55Z","timestamp":1791530155596,"version":"4.3.4"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Clear cell renal cell carcinoma (ccRCC) most commonly metastasizes to the lungs, lymph nodes, bones, and liver. Metastasis to the breast is exceptionally rare, representing less than 0.5% of cases. Herein, we report an unprecedented case of triple metastasis with the longest recorded latency period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>An 86-year-old female presented with a painless left breast mass 25 years after undergoing radical nephrectomy for ccRCC. Multi-modality imaging (mammography, ultrasound, MRI) revealed a suspicious breast lesion. Subsequent chest CT and PET-CT identified synchronous metastatic nodules in the lungs and brain. Histopathological examination of the resected breast mass confirmed metastatic carcinoma. The diagnosis of ccRCC metastasis was substantiated by an immunohistochemical profile positive for PAX8, CAIX, and CD10, while negative for estrogen receptor, progesterone receptor, and HER2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case highlights breast metastasis as a rare but critical differential diagnosis in patients with a history of ccRCC, even decades after initial treatment. It underscores the necessity of lifelong follow-up for ccRCC survivors and demonstrates the integral role of imaging and pathological confirmation in guiding clinical diagnosis. Furthermore, the remarkable 25-year latency period challenges existing surveillance paradigms and provides a compelling rationale for the use of combined immunotherapy and targeted agents in managing ultra-late, multi-metastatic recurrences.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1733997","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T05:36:48Z","timestamp":1768973808000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Ultra-late triple metastasis to the breast, lung, and brain 25 years after nephrectomy for clear cell renal cell carcinoma: a case report and literature review"],"prefix":"10.3389","volume":"16","author":[{"given":"Sujian","family":"Xiao","sequence":"first","affiliation":[{"name":"Department of Breast, The Affiliated Ganzhou Hospital, Jiangxi Medical College, Nanchang University","place":["Jiangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Urology, The Affiliated Ganzhou Hospital, Jiangxi Medical College, Nanchang University","place":["Jiangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Deng","sequence":"additional","affiliation":[{"name":"Infectious Disease Department, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University","place":["Nanchang, Jiangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Urology, The Affiliated Ganzhou Hospital, Jiangxi Medical College, Nanchang University","place":["Jiangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuance","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Urology, The Affiliated Ganzhou Hospital, Jiangxi Medical College, Nanchang University","place":["Jiangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huozhong","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Breast, The Affiliated Ganzhou Hospital, Jiangxi Medical College, Nanchang University","place":["Jiangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Li","sequence":"additional","affiliation":[{"name":"Pathology Department, The Affiliated Ganzhou Hospital, Jiangxi Medical College, Nanchang University","place":["Jiangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiliang","family":"Zhai","sequence":"additional","affiliation":[{"name":"Department of Urology, The Affiliated Ganzhou Hospital, Jiangxi Medical College, Nanchang University","place":["Jiangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.12848","article-title":"Renal cell carcinoma: A review","volume":"332","author":"Rose","year":"2024","journal-title":"JAMA"},{"key":"B2","first-page":"2022","article-title":"Renal cell carcinoma: an overview of the epidemiology, diagnosis, and treatment","volume":"39","author":"Bahadoram","year":"2022","journal-title":"G Ital Nefrol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.07.039","article-title":"Metastatic renal cell carcinoma: results of a population-based study with 25 years follow-up","volume":"44","author":"Schlesinger-Raab","year":"2008","journal-title":"Eur J Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.21869","article-title":"Evaluation of clear cell, papillary, and chromophobe renal cell carcinoma metastasis sites and association with survival","volume":"4","author":"Dudani","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B5","doi-asserted-by":"publisher","first-page":"rjac116","DOI":"10.1093\/jscr\/rjac116","article-title":"Breast metastasis 18 years after nephrectomy for renal cell carcinoma: a case report","volume":"2022","author":"Elouarith","year":"2022","journal-title":"J Surg Case Rep"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2451093","DOI":"10.1002\/eji.202451093","article-title":"Characteristics and mechanisms of T-cell senescence: A potential target for cancer immunotherapy","volume":"54","author":"Wu","year":"2024","journal-title":"Eur J Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1038\/s41467-024-46769-9","article-title":"Senescence drives immunotherapy resistance by inducing an immunosuppressive tumor microenvironment","volume":"15","author":"Maggiorani","year":"2024","journal-title":"Nat Commun"},{"key":"B8","doi-asserted-by":"publisher","first-page":"156335","DOI":"10.1016\/j.cyto.2023.156335","article-title":"Chemokines and receptors in the development and progression of Malignant tumors","volume":"170","author":"Hq Z","year":"2023","journal-title":"Cytokine"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2021.06.004","article-title":"Cellular stress responses and metabolic reprogramming in cancer progression and dormancy","volume":"78","author":"Kk","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/dc.24710","article-title":"Metastatic clear cell renal cell carcinoma presenting as breast lump: A rare case report","volume":"49","author":"Verma","year":"2021","journal-title":"Diagn Cytopathol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.48352","article-title":"Clinically silent, metastatic renal cell carcinoma detected on routine screening mammogram: A report of a rare case and review of literature","volume":"15","author":"Pernicone","year":"2023","journal-title":"Cureus"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.radcr.2021.02.006","article-title":"Metastatic renal cell carcinoma initially presenting as a unilateral breast lump","volume":"16","author":"Khurram","year":"2021","journal-title":"Radiol Case Rep"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.82801","article-title":"Gastric metastasis from clear cell renal cell carcinoma: A case report","volume":"17","author":"Gon\u00e7alves","year":"2025","journal-title":"Cureus"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3873","article-title":"Clinical impact of follow-up imaging on mortality in Korean breast cancer patients: A national cohort study","volume":"10","author":"Jung","year":"2021","journal-title":"Cancer Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-022-02459-8","article-title":"Immunoglobulin superfamily 9 (IGSF9) is trans-activated by p53, inhibits breast cancer metastasis via FAK","volume":"41","author":"Li","year":"2022","journal-title":"Oncogene"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202404904","article-title":"ZNF8 orchestrates with smad3 to promote lung metastasis by recruiting SMYD3 in breast cancer","volume":"11","author":"Geng","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.12659\/msm.896563","article-title":"Assessing clinical significance of serum CA15\u20133 and carcinoembryonic antigen (CEA) levels in breast cancer patients: A meta-analysis","volume":"22","author":"Fu","year":"2016","journal-title":"Med Sci Monit"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/jcu.23504","article-title":"Multimodal ultrasonography of male primary breast lymphoma","volume":"51","author":"Lyu","year":"2023","journal-title":"J Clin Ultrasound"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1256146","article-title":"A clinical-radiomics nomogram based on multimodal ultrasound for predicting the Malignancy risk in solid hypoechoic breast lesions","volume":"13","author":"Shiyan","year":"2023","journal-title":"Front Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02475","article-title":"Surveillance imaging after curative-intent treatment for cancer: benefits, harms, and evidence","volume":"42","author":"Wilson","year":"2024","journal-title":"JCO"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2025.02.020","article-title":"European association of urology guidelines on renal cell carcinoma: the 2025 update","volume":"87","author":"Bex","year":"2025","journal-title":"Eur Urol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2015.12.094","article-title":"Comparison of renal cell carcinoma surveillance guidelines: competing trade-offs","volume":"195","author":"Lobo","year":"2016","journal-title":"J Urol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0142-8","article-title":"Cancer overdiagnosis: a biological challenge and clinical dilemma","volume":"19","author":"Srivastava","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2014.013","article-title":"Which Patients Should We Follow up beyond 5 Years after Definitive Therapy for Localized Renal Cell Carcinoma","volume":"47","author":"Lee","year":"2015","journal-title":"Cancer Res Treat"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/iju5.12422","article-title":"Case Study: A Japanese patient with metastatic renal cell carcinoma who achieved long-term treatment-free survival with pembrolizumab and axitinib in the KEYNOTE-426 phase III trial of pembrolizumab and axitinib versus sunitinib","volume":"5","author":"Nishimoto","year":"2022","journal-title":"IJU Case Rep"},{"key":"B26","doi-asserted-by":"publisher","first-page":"79","DOI":"10.21037\/cco-23-159","article-title":"Combining immunotherapy\/targeted therapy with hepatic artery chemo-infusion in treating patients with advanced hepatocellular carcinoma","volume":"13","author":"Son","year":"2024","journal-title":"Chin Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1733997\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T07:39:20Z","timestamp":1771918760000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1733997\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,21]]},"references-count":27,"alternative-id":["10.3389\/fonc.2026.1733997"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1733997","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,21]]},"article-number":"1733997"}}